Drug Cos. May Rethink Patent Strategy After Fed. Circ. Ruling
A recent Federal Circuit ruling could reinvigorate certain types of challenges to pharmaceutical patents and force drugmakers to rethink the way they go about protecting some inventions, attorneys say....To view the full article, register now.
Already a subscriber? Click here to view full article